Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Immunoevasive Mecanisms and Especially Myeloid Suppressive Cells in the Medullar Microenvironment Employed by Myeloid Malignancy (AML and High Risk MDS) When Relapsing After Allogeneic Stem Cell Transplantation

NCT03964922 is registered in ClinicalTrials.gov with Central Hospital, Nancy, France as lead sponsor.

NCT NCT03964922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03964922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Immunoevasive Mecanisms and Especially Myeloid Suppressive Cells in the Medullar Microenvironment Employed by Myeloid Malignancy (AML and High Risk MDS) When Relapsing After Allogeneic Stem Cell Transplantation
Lead sponsor
Central Hospital, Nancy, France
Phase
Not applicable
Overall status
Unknown status
Start date
September 1, 2019
Completion date
November 1, 2022
Enrollment
104 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic stem cell transplantation, immune evasion, tumor, relapse leukemia